185 related articles for article (PubMed ID: 15592494)
21. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Kashyap A; Wingard J; Cagnoni P; Roy J; Tarantolo S; Hu W; Blume K; Niland J; Palmer JM; Vaughan W; Fernandez H; Champlin R; Forman S; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):493-500. PubMed ID: 12374454
[TBL] [Abstract][Full Text] [Related]
22. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.
de Magalhaes-Silverman M; Lister J; Rybka W; Wilson J; Ball E
Bone Marrow Transplant; 1997 Apr; 19(8):777-81. PubMed ID: 9134168
[TBL] [Abstract][Full Text] [Related]
23. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
[TBL] [Abstract][Full Text] [Related]
24. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma.
Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR
Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653
[TBL] [Abstract][Full Text] [Related]
25. [The toxicity of busulphan and cyclophosphamide as the preparative regimen for allogeneic peripheral blood stem cell transplantation].
Zhu K; Xu Y; Wu D; Xu X; Huang L
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):403-5. PubMed ID: 11877010
[TBL] [Abstract][Full Text] [Related]
26. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
27. Lorazepam for seizure prophylaxis during high-dose busulfan administration.
Chan KW; Mullen CA; Worth LL; Choroszy M; Koontz S; Tran H; Slopis J
Bone Marrow Transplant; 2002 Jun; 29(12):963-5. PubMed ID: 12098063
[TBL] [Abstract][Full Text] [Related]
28. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
29. Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases.
Fujii N; Maeda Y; Takenaka K; Shinagawa K; Imai T; Kozuka T; Ikeda K; Sunami K; Hiramatsu Y; Ishimaru F; Niiya K; Harada M
Int J Hematol; 2000 Dec; 72(4):499-503. PubMed ID: 11197220
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation].
Zhang GC; Zheng D; Guan XX; Luo SK; Li J; Peng AH; Tong XZ; Lai FZ; Tan EX; Hong WD
Ai Zheng; 2003 Jun; 22(6):620-3. PubMed ID: 12948413
[TBL] [Abstract][Full Text] [Related]
31. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.
Andersson BS; Kashyap A; Gian V; Wingard JR; Fernandez H; Cagnoni PJ; Jones RB; Tarantolo S; Hu WW; Blume KG; Forman SJ; Champlin RE
Biol Blood Marrow Transplant; 2002; 8(3):145-54. PubMed ID: 11939604
[TBL] [Abstract][Full Text] [Related]
32. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Rossi HA; Becker PS; Emmons RV; Westervelt P; Levy W; Liu Q; Clark Y; Ballen K
Bone Marrow Transplant; 2003 Mar; 31(6):441-6. PubMed ID: 12665838
[TBL] [Abstract][Full Text] [Related]
33. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
34. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.
Schiller G; Nimer S; Vescio R; Lieb G; Lee M; Gajewski J; Territo M; Berenson J
Bone Marrow Transplant; 1994 Jul; 14(1):131-6. PubMed ID: 7951100
[TBL] [Abstract][Full Text] [Related]
37. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
38. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.
Fujimaki K; Maruta A; Yoshida M; Sakai R; Tanabe J; Koharazawa H; Kodama F; Asahina S; Minamizawa M; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Bone Marrow Transplant; 2001 Feb; 27(3):307-10. PubMed ID: 11277179
[TBL] [Abstract][Full Text] [Related]
39. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
Copelan EA; Bechtel TP; Avalos BR; Elder PJ; Ezzone SA; Scholl MD; Penza SL
Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
Fernandez HF; Tran HT; Albrecht F; Lennon S; Caldera H; Goodman MS
Biol Blood Marrow Transplant; 2002; 8(9):486-92. PubMed ID: 12374453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
